Uncomplicated Urinary Tract Infection Market Size Expected to Witness Significant Growth by 2034, estimates DelveInsight
DelveInsight’s “Uncomplicated Urinary Tract Infection (uUTI) Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of uUTI, historical and forecasted epidemiology, as well as the Uncomplicated Urinary Tract Infection market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover Key Insights into the Uncomplicated Urinary Tract Infection Market with DelveInsight’s In-Depth Report @ Uncomplicated Urinary Tract Infection Market Size
Key Takeaways from the Uncomplicated Urinary Tract Infection Market Report
-
The leading Uncomplicated Urinary Tract Infection companies include Iterum Therapeutics, GlaxoSmithKline, Inmunotek, Locus Biosciences, and others.
-
Rising prevalence of UTIs globally, driven by lifestyle changes, increasing antibiotic resistance, and recurrent infection burden, is accelerating demand for novel therapeutic options offering effective and durable outcomes.
-
Breakthroughs in novel antibacterial classes, bacteriophage-CRISPR therapies, sublingual bacterial vaccines, and combination antibiotic formulations are expanding the therapeutic landscape and improving clinical outcomes.
-
The United States accounted for the highest uUTI market share across the 7MM, representing approximately 60% of the total market in 2023, with the US market valued at approximately USD 500 million.
-
Key targets currently under development include bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), OAT3-mediated renal clearance pathways, sublingual immunostimulation, and CRISPR-Cas3-enhanced bacteriophage mechanisms, among others.
Stay ahead in the Uncomplicated Urinary Tract Infection Market with DelveInsight’s Strategic Report @ Uncomplicated Urinary Tract Infection Market Outlook
Uncomplicated Urinary Tract Infection Epidemiology Segmentation in the 7MM
-
Total Uncomplicated Urinary Tract Infection Occurrence-specific Cases
-
Total Uncomplicated Urinary Tract Infection Diagnosed Cases
-
Uncomplicated Urinary Tract Infection Age Group-specific Cases
-
Uncomplicated Urinary Tract Infection Pathogen-specific Cases
-
Total Uncomplicated Urinary Tract Infection Treated Cases
Uncomplicated Urinary Tract Infection Pipeline Analysis
ORLYNVAH (sulopenem etzadroxil/probenecid): Iterum Therapeutics
ORLYNVAH is a fixed-dose combination of sulopenem etzadroxil, a penem antibacterial, and probenecid, which inhibits OAT3-mediated renal clearance to increase sulopenem plasma concentrations. Approved by the US FDA in October 2024 for the treatment of uUTI in adult women, it is indicated for infections caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, particularly when alternative oral antibacterial options are limited. It holds both Special Protocol Agreement (SPA) and Qualified Infectious Disease Product (QIDP) designations under the GAIN Act.
Gepotidacin (GSK2140944): GlaxoSmithKline
Gepotidacin is a first-in-class triazaacenaphthylene bacterial type II topoisomerase inhibitor developed under a public-private partnership between GSK, BARDA, and DTRA. It works by selectively targeting two key bacterial enzymes — DNA gyrase and topoisomerase IV — responsible for bacterial replication, with a mechanism of action distinct from any currently approved antibiotic. In March 2025, the FDA approved gepotidacin (Blujepa) for treating uUTIs in female adults and pediatric patients aged 12 years and older. By 2034, gepotidacin is expected to generate nearly USD 1,000 million in revenue in the United States alone.
UROMUNE (MV140): Inmunotek
UROMUNE is a glycerinated suspension of whole cell-inactivated bacteria administered via sublingual spray. Currently in Phase III development, it is already accessible through named patient programs in 26 countries including the UK, Germany, Spain, Netherlands, and New Zealand. An expanded access program targets patients with recurrent or chronic UTIs unresponsive to antibiotics.
LBP-EC01: Locus Biosciences
LBP-EC01 is a CRISPR-Cas3-enhanced bacteriophage therapy with a dual mechanism of action, administered intravenously or intravesically via catheter. Currently in Phase II/III development, it represents one of the most innovative approaches in the uUTI pipeline, targeting unmet needs in antibiotic-resistant infections.
Uncomplicated Urinary Tract Infection Market Insights
The current treatment landscape centers on antibiotics as the gold standard, with commonly prescribed agents including trimethoprim-sulfamethoxazole (TMP-SMX), trimethoprim, β-lactams, fluoroquinolones, nitrofurantoin, and fosfomycin tromethamine.
The FDA approval of ORLYNVAH in October 2024 marked a major milestone, representing the first new drug approval for uUTI in years and filling a critical therapeutic gap after a prolonged period without innovation.
The competitive landscape is rapidly evolving, with leading players advancing novel antibacterial classes, bacteriophage platforms, and immunostimulatory vaccines to address antibiotic resistance and recurrent infection challenges.
The burden of recurrent uUTI, inappropriate empirical treatment, and declining effectiveness of existing antibiotics continue to constrain the market, while antibiotic stewardship programs and non-antibiotic prophylaxis strategies are gaining traction as complementary approaches.
The expected introduction of emerging therapies with improved mechanisms, greater diagnostic precision, and expanded access programs is likely to boost market growth across the 7MM through the forecast period.
Get In-Depth Knowledge on Uncomplicated Urinary Tract Infection Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/report-store/uncomplicated-urinary-tract-infection-uuti-market
Uncomplicated Urinary Tract Infection Market Outlook
Uncomplicated urinary tract infection is the most common bacterial infection globally, predominantly affecting women, with research suggesting that 40–60% of women develop a UTI during their lifetime and one in four experiencing a repeat infection. Caused most commonly by Uropathogenic Escherichia coli (UPEC) — responsible for approximately 75% of cases — alongside Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis, and Staphylococcus saprophyticus, uUTI places a significant and growing burden on healthcare systems. The uUTI pipeline is increasingly robust, with multiple candidates across Phase II and Phase III development, and the treatment landscape is expected to undergo a meaningful positive shift during the forecast period. Market growth may be tempered by challenges including antibiotic resistance, reimbursement barriers, high therapy costs, and the misuse of empirical treatment protocols.
Scope of the Uncomplicated Urinary Tract Infection Market Report
-
Coverage: 7MM
-
Study Period: 2020–2034
-
Forecast Period: 2024–2034
-
Uncomplicated Urinary Tract Infection Companies: Iterum Therapeutics, GlaxoSmithKline, Inmunotek, Locus Biosciences, and others
-
Uncomplicated Urinary Tract Infection Therapies: ORLYNVAH, Gepotidacin, UROMUNE (MV140), LBP-EC01, and others
-
Uncomplicated Urinary Tract Infection Market Access & Reimbursements, Unmet Needs and Perspectives
-
Uncomplicated Urinary Tract Infection SWOT Analysis and KOL Views
Unlock Strategic Insights with DelveInsight’s Comprehensive Uncomplicated Urinary Tract Infection Market Report @ Uncomplicated Urinary Tract Infection Market Drivers and Barriers
Table of Contents
-
Key Insights
-
Report Introduction
-
Uncomplicated Urinary Tract Infection (uUTI) Market Overview at a Glance
-
Methodology
-
Executive Summary
-
Key Events
-
Disease Background and Overview
-
Current Treatment Practices of Uncomplicated UTI
-
Epidemiology and Patient Population
-
Patient Journey
-
Marketed Therapy
-
Emerging Therapies
-
Market Analysis
-
KOL Views
-
SWOT Analysis
-
Unmet Needs
-
Market Access and Reimbursement
-
Appendix
-
DelveInsight Capabilities
-
Disclaimer
Related Reports
Uncomplicated Urinary Tract Infection – Epidemiology Forecast – 2034
Urinary tract infection (UTI) is caused by a range of pathogens, but most commonly by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis, and Staphylococcus saprophyticus. A UTI can develop in any part of the urinary tract, including the urethra, bladder, ureters, or kidneys. A UTI (also known as a bladder infection) is a common condition that occurs when bacteria migrate into the usually sterile urinary tract and multiply. Bladder infections are common, especially among women. Research suggests that at least 40–60% of women develop a UTI during their lifetime, and most of these infections are bladder infections. One in four women is likely to have a repeat infection. UTI is classified as either complicated or uncomplicated.
Uncomplicated Urinary Tract Infections – Pipeline Insight, 2026
DelveInsight’s, “Uncomplicated Urinary Tract Infections – Pipeline Insight, 2026” report provides comprehensive insights about 4+ companies and 5+ pipeline drugs in Uncomplicated Urinary Tract Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/uncomplicated-urinary-tract-infection-uuti-market
